Skip To Main Content
Paul Hampel on Muck Rack

Paul Hampel

St. Louis
As seen in: Nature, Wiley Online Library, The Atlanta Journal-Constitution, St. Louis Post-Dispatch, Herald & Review, Texas Medical Center, Patient Power
Oldest of six. Father of four. Responsible for everything. St. Louis County government. Ex-Post-Dispatch reporter.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Paul

Contact Paul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Unraveling Cancer Podcast: Fixed vs. Continuous CLL Treatment Explained

|
By Brad Adams, Paul Hampel
| Patient Power Verified
In this episode of the Patient Power podcast, Unraveling Cancer, patient host Brad Adams is joined by Paul J. Hampel, MD, a hematologist-oncologist at Mayo Clinic in Rochester, for a conversation about fixed duration versus continuous treatment for chronic lymphocytic leukemia (CLL), including benefits, side effects, monitoring, and how to choose the best option based on your lifestyle and disease features. © 2026 HealthCentral LLC. All rights reserved.
Open in Who Shared Issue with article?

Central nervous system involvement in patients with Richter transformation of chronic lymphocytic leukemia (CLL): the Mayo Clinic experience - Blood Cancer Journal

|
By Suheil Albert Atallah-Yunes, Paul Hampel, Saad S. Kenderian, Eli Muchtar, Neil E Kay, Grzegorz Nowakowski, Thomas M Habermann, Talal Hilal, Ricardo D. Parrondo, Rong Lucy He, Sameer A Parikh, Domitilla Baccon
| Nature Verified
To the Editor: Richter transformation (RT) is the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). RT involving the central nervous system (RT-CNS) is rare with existing knowledge largely limited to case reports and small series, leaving major gaps in understanding its clinicopathologic features, prognostic markers, and optimal management [1,2,3,4,5].
Open in Who Shared Issue with article?

Clearer CLL Treatment Choices: New BTK Inhibitors, Degraders, and Expert Updates

|
By Kerry Rogers, Paul Hampel, Catherine Callaghan Coombs
| Patient Power Verified
From the 2025 American Society of Hematology Annual Meeting, Kerry Rogers, MD, is joined by Paul Hampel, MD, and Catherine Coombs, MD, to discuss clearer chronic lymphocytic leukemia (CLL) treatment choices, including new BTK inhibitors, emerging BTK degraders, and expert updates to help patients better understand evolving options.
Open in Who Shared Issue with article?
See all 198 articles